Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Non Operating Income (2016 - 2025)

Adma Biologics' Non Operating Income history spans 13 years, with the latest figure at -$8.6 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 190.77% year-over-year to -$8.6 million; the TTM value through Dec 2025 reached -$8.8 million, down 432.77%, while the annual FY2025 figure was -$8.8 million, 4452.85% down from the prior year.
  • Non Operating Income reached -$8.6 million in Q4 2025 per ADMA's latest filing, down from -$21000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $9.5 million in Q4 2024 to a low of -$49.7 million in Q4 2023.
  • Average Non Operating Income over 5 years is -$5.4 million, with a median of -$3.3 million recorded in 2021.
  • The largest YoY upside for Non Operating Income was 119.05% in 2024 against a maximum downside of 25669.23% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$13.2 million in 2021, then skyrocketed by 53.12% to -$6.2 million in 2022, then tumbled by 704.84% to -$49.7 million in 2023, then soared by 119.05% to $9.5 million in 2024, then tumbled by 190.77% to -$8.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Non Operating Income are -$8.6 million (Q4 2025), -$21000.0 (Q3 2025), and -$108000.0 (Q2 2025).